Comparing Avalo Therapeutics (NASDAQ:AVTX) & Opus Genetics (NASDAQ:IRD)

Avalo Therapeutics (NASDAQ:AVTX) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Profitability

This table compares Avalo Therapeutics and Opus Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-34.21%	-29.84%
Opus Genetics	-1,726.70%	N/A	-146.19%

Analyst Recommendations

This is a summary of current recommendations and price targets for Avalo Therapeutics and Opus Genetics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1	2	11	0	2.71
Opus Genetics	1	1	16	1	2.89

Avalo Therapeutics currently has a consensus price target of $36.82, suggesting a potential upside of 348.67%. Opus Genetics has a consensus price target of $13.29, suggesting a potential upside of 222.86%. Given Avalo Therapeutics’ higher probable upside, equities analysts clearly believe Avalo Therapeutics is more favorable than Opus Genetics.

Insider & Institutional Ownership

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by insiders. Comparatively, 11.7% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Avalo Therapeutics and Opus Genetics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$59,000.00	8,042.30	-$78.26 million	($2.52)	-3.26
Opus Genetics	$14.20 million	23.95	-$49.59 million	($1.35)	-3.05

Opus Genetics has higher revenue and earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Avalo Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

Summary

Opus Genetics beats Avalo Therapeutics on 10 of the 15 factors compared between the two stocks.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. The company does not have marketed products and is centered on advancing drug candidates through clinical development. Its lead candidate, AVTX-009, is a monoclonal antibody that targets interleukin-1 beta (IL-1?), an inflammatory signaling protein. Avalo is developing the therapy for hidradenitis suppurativa, a chronic inflammatory skin disease, and has described potential applications in other inflammatory conditions.

About Opus Genetics

Opus Genetics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases, rare conditions that can cause progressive vision loss. Its programs target specific genetic causes of these disorders, including mutations associated with Leber congenital amaurosis and retinitis pigmentosa. The company’s therapies are investigational and are designed to address the underlying genetic defects rather than only manage symptoms. Opus Genetics was formed through the combination of Opus Genetics and Ocuphire Pharma; the combined company took the Opus Genetics name and began trading on Nasdaq under the symbol IRD in 2024.